Bruton Kinase Inhibitors (BTKi) Use in MS Treatment
BTK inhibitor implementation for MS treatment is explored.
Switching Agents Due to Underwhelming MS Treatment Response Rates
The panelists provide insights into the decision-making process behind switching MS treatment strategies due to lacking or failed therapies.
Real-World Evidence in HIV
Key opinion leaders discuss the value of real-world evidence in the management of HIV.
Evaluating Effectiveness of A Patient's Current HIV Treatment Regimen
Assessing the quality of an HIV treatment plan is crucial to patient prognosis.
Unmet Needs Surrounding RSV Treatments
In her closing thoughts, Dr Filer provides insights into the unmet needs in the treatment of RSV.
Promoting Awareness for RSV Vaccines: Part 2
Discussion surrounding promotion of RSV vaccine awareness is further discussed.
Promoting Awareness for RSV Vaccines: Part 1
The panel offers strategies for being proactive .
Mitigating Clinical Inertia in MS Treatment Through Payer-Provider Collaboration
Dr Haumschild leads a discussion surrounding patient and provider collaboration to avoid clinical inertia in MS treatment pathways.
Early Treatment and Frontline Therapies for Patients with MS
Frontline treatment options and the benefits of early intervention of MS are illustrated.
Navigating HIV Treatment Barriers Associated with Pill Burden
Medical experts discuss the significance of pill burden in the HIV treatment pathway.
Long-Acting Injectables in the HIV Treatment Landscape
The role of and indication for long-acting injectables is highlighted as a treatment approach for HIV.
Payer Considerations for RSV Vaccine Coverage
Experts discuss the financial needs for RSV vaccines through a payer lens.
Navigating the RSV Treatment Landscape and Associated Financial Considerations
Financial burden associated with RSV treatment is explored by a medical expert.
Addressing Barriers Surrounding RSV Vaccines
Experts highlight the potential obstacles for RSV vaccines.
Current MS Treatment Paradigms
Key opinion leaders highlight the MS treatment landscape.
Financial Burden for Patients Diagnosed with MS
An expert panel discusses cost burden associated with the treatment of MS.
Individualized Care for Specific Patient Populations Elevating Outcomes in Women's Health
The panelists provide their final thoughts regarding disparities in women’s health.
Overview of Current HIV Treatment Strategies
The treatment landscape for HIV is discussed by a panel led by Dr Welch.
Guideline-Directed HIV Therapies
Key opinion leaders discuss the influence of guideline-directed therapy in the treatment of patients with HIV.
Navigating Vaccine Hesitancy
Vaccine hesitancy is a significant barrier to optimal RSV vaccine rollout.
Anticipating Needs of Patients Diagnosed with RSV
Experts discuss strategies to prepare for the oncoming respiratory diseases season.
Opportunities and Challenges Facing RSV Vaccination Rollouts
Dr Filer highlights the considerations for the rollout of new RSV vaccines.
MS Disease Activity Versus Inactivity
The pathophysiology and treatment of active and inactive MS are explored.
Overview of Multiple Sclerosis Epidemiology
Ryan Haumschild, PharmD, MS, MBA, leads a discussion around the epidemiology of multiple sclerosis.
Challenges with TNBC Influenced by Racial Disparities
Drs Derek van Amerongen, Soyini Hawkins, Roxie Cannon Wells, and Sharon Deans highlight triple-negative breast cancer among underrepresented patient populations.
Community-Based Screening Initiatives in Women's Health
The panel highlights initiatives to aid women in early cervical cancer diagnosis and intervention.
Social and Clinical Barriers Associated with HIV
An expert panel navigates stigmas and barriers inhibiting patients from achieving optimal care for HIV.
Barriers to Obtaining Optimal HIV Treatment
Dr Adam C. Welch drives a discussion highlighting disparities in health care equity affecting patients who receive an HIV diagnosis.
RSV Outcomes in Infant, Pediatric, and Adult Patient Populations
Wanda Filer, MD, MBA, FAAFP, provides an overview of the potential outcomes for patients of all ages with RSV.
Clinical Trials Surrounding Effectiveness of RSV Vaccine
Key opinion leaders discuss ongoing clinical trials for respiratory syncytial virus vaccines.
